- Home
- MNRO vs ANAB Comparison
MNRO vs ANAB Comparison
Compare MNRO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNRO
- ANAB
- Stock Information
- Founded
- MNRO 1957
- ANAB 2005
- Country
- MNRO United States
- ANAB United States
- Employees
- MNRO N/A
- ANAB N/A
- Industry
- MNRO Automotive Aftermarket
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- MNRO Consumer Discretionary
- ANAB Health Care
- Exchange
- MNRO Nasdaq
- ANAB Nasdaq
- Market Cap
- MNRO 658.9M
- ANAB 759.5M
- IPO Year
- MNRO 1991
- ANAB 2017
- Fundamental
- Price
- MNRO $12.76
- ANAB $19.58
- Analyst Decision
- MNRO Buy
- ANAB Buy
- Analyst Count
- MNRO 4
- ANAB 10
- Target Price
- MNRO $20.75
- ANAB $37.75
- AVG Volume (30 Days)
- MNRO 710.6K
- ANAB 605.6K
- Earning Date
- MNRO 05-22-2025
- ANAB 05-05-2025
- Dividend Yield
- MNRO 8.72%
- ANAB N/A
- EPS Growth
- MNRO N/A
- ANAB N/A
- EPS
- MNRO 0.62
- ANAB N/A
- Revenue
- MNRO $1,210,419,000.00
- ANAB $111,872,000.00
- Revenue This Year
- MNRO N/A
- ANAB N/A
- Revenue Next Year
- MNRO $2.89
- ANAB $44.69
- P/E Ratio
- MNRO $20.84
- ANAB N/A
- Revenue Growth
- MNRO N/A
- ANAB 387.20
- 52 Week Low
- MNRO $13.50
- ANAB $12.21
- 52 Week High
- MNRO $31.49
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- MNRO 29.54
- ANAB 48.91
- Support Level
- MNRO $13.53
- ANAB $19.57
- Resistance Level
- MNRO $14.40
- ANAB $21.52
- Average True Range (ATR)
- MNRO 0.51
- ANAB 1.19
- MACD
- MNRO -0.06
- ANAB -0.22
- Stochastic Oscillator
- MNRO 9.47
- ANAB 26.72
About MNRO Monro Inc.
Monro Inc is a provider automobile service stations in the United States. Through its network of company-owned service stations, Monro Muffler Brake offers maintenance, repair, tire, and fleet management services for automobiles focused largely on undercar services such as brake, steering, exhaust, drivetrain, and suspension systems. Next to service stores, the company also offers tire stores specialised in tire replacement and service.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).